Year archive

Laekna, Inc. — 2024 filings

All 50 regulatory filings released by Laekna, Inc. (2105) in 2024, sourced directly from the official regulator.

50 Filings

2024 Period

2024 filings (50)

Filing	Released	Lang
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024 Regulatory Filings	2024-12-05	English
VOLUNTARY ANNOUNCEMENT ALL SUBJECTS IN PHASE I SAD STUDY OF LAE102 HAVE BEEN DOSED FOR THE TREATMENT OF OBESITY Regulatory Filings	2024-12-03	English
VOLUNTARY ANNOUNCEMENT IND-ENABLING STUDY INITIATED FOR LAE123 FOR THE TREATMENT OF SEVERE DISEASES Regulatory Filings	2024-11-28	English
Next Day Disclosure Return Share Issue/Capital Change	2024-11-27	English
COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE Share Issue/Capital Change	2024-11-27	English
PLACING OF NEW SHARES UNDER GENERAL MANDATE Regulatory Filings	2024-11-21	English
VOLUNTARY ANNOUNCEMENT CLINICAL COLLABORATION WITH LILLY ON LAE102 IN THE U.S. FOR THE TREATMENT OF OBESITY Regulatory Filings	2024-11-20	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024 Regulatory Filings	2024-11-05	English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 18 OCTOBER 2024 Regulatory Filings	2024-10-18	English
VOLUNTARY ANNOUNCEMENT SUBCUTANEOUS COHORT INITIATED IN PHASE I CLINICAL TRIAL OF LAE102 FOR THE TREATMENT OF OBESITY Regulatory Filings	2024-10-18	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024 Regulatory Filings	2024-10-07	English
NOTICE OF EXTRAORDINARY GENERAL MEETING Regulatory Filings	2024-09-27	English
PROXY FORM FOR THE EXTRAORDINARY GENERAL MEETING Regulatory Filings	2024-09-27	English
(1) PROPOSED GRANT OF RSUs TO DIRECTORS UNDER THE 2024 SHARE AWARD SCHEME; AND (2) NOTICE OF EXTRAORDINARY GENERAL MEETING Regulatory Filings	2024-09-27	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024 Regulatory Filings	2024-09-05	English
GRANT OF RESTRICTED SHARE UNITS Regulatory Filings	2024-09-05	English
Interim Report 2024 Regulatory Filings	2024-08-26	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024 Regulatory Filings	2024-08-16	English
DATE OF BOARD MEETING Regulatory Filings	2024-08-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024 Regulatory Filings	2024-08-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024 Regulatory Filings	2024-07-05	English
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT DOSED IN PHASE I CLINICAL TRIAL OF LAE102 FOR THE TREATMENT OF OBESITY Regulatory Filings	2024-06-26	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 14 JUNE 2024 Regulatory Filings	2024-06-14	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024 Regulatory Filings	2024-06-05	English
2024 Share Award Scheme Regulatory Filings	2024-05-30	English
VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OF LAE002 (AFURESERTIB) PLUS FULVESTRANT IN PATIENTS WITH HR+/HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER Regulatory Filings	2024-05-30	English
VOLUNTARY ANNOUNCEMENT APPROVAL BY THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE PHASE III CLINICAL TRIAL PROTOCOL OF LAE002 (AFURESERTIB) PLUS LAE001 FOR THE TREATMENT OF PROSTATE CANCER Regulatory Filings	2024-05-23	English
PROXY FORM FOR THE ANNUAL GENERAL MEETING Regulatory Filings	2024-05-22	English
NOTICE OF ANNUAL GENERAL MEETING Regulatory Filings	2024-05-22	English
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES, RESELL TREASURY SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF DIRECTORS; PROPOSED RE-APPOINTMENT OF AUDITOR; PROPOSED ADOP Regulatory Filings	2024-05-22	English
PROPOSED ADOPTION OF THE SHARE AWARD SCHEME Regulatory Filings	2024-05-21	English
VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR LAE102 FOR THE TREATMENT OF OBESITY WAS OBTAINED FROM THE CENTRE FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHI Regulatory Filings	2024-05-10	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024 Regulatory Filings	2024-05-07	English
2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Regulatory Filings	2024-04-26	English
2023 ANNUAL REPORT Regulatory Filings	2024-04-26	English
VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR LAE102 FOR THE TREATMENT OF OBESITY WAS OBTAINED FROM THE U.S. FOOD AND DRUG ADMINISTRATION Regulatory Filings	2024-04-15	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024 Regulatory Filings	2024-04-03	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 Regulatory Filings	2024-03-26	English
VOLUNTARY ANNOUNCEMENT SUBMISSION OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LAE102 FOR THE TREATMENT OF OBESITY TO THE U.S. FOOD AND DRUG ADMINISTRATION Regulatory Filings	2024-03-11	English
DATE OF BOARD MEETING Regulatory Filings	2024-03-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024 Regulatory Filings	2024-03-05	English
Letter to Non-Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form Regulatory Filings	2024-03-01	English
Letter to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form Regulatory Filings	2024-03-01	English
VOLUNTARY ANNOUNCEMENT THE CENTRE FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE INVESTIGATIONAL NEW DRUG APPLICATION FOR LAE102 Regulatory Filings	2024-02-29	English
CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE, AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES Regulatory Filings	2024-02-02	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024 Regulatory Filings	2024-02-02	English
VOLUNTARY ANNOUNCEMENT - TOP-LINE READOUT OF AFURESERTIB PLUS PACLITAXEL FOR PROC (PROFECTA-II) Regulatory Filings	2024-01-28	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Regulatory Filings	2024-01-15	English
(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND COMPOSITION OF BOARD COMMITTEES; AND (2) APPOINTMENT OF CHIEF FINANCIAL OFFICER Regulatory Filings	2024-01-15	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023 Regulatory Filings	2024-01-05	English